Back to User profile » Prof. Dr. Rupert Handgretinger
Papers published by Prof. Dr. Rupert Handgretinger:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Antiemetic Prophylaxis with Fosaprepitant and 5-HT3-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
Cabanillas Stanchi KM, Willier S, Vek J, Schlegel P, Queudeville M, Rieflin N, Klaus V, Gansel M, Rupprecht JV, Flaadt T, Binder V, Feuchtinger T, Lang P, Handgretinger R, Döring M
Drug Design, Development and Therapy 2020, 14:3915-3927
Published Date: 25 September 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies
Cabanillas Stanchi KM, Ebinger M, Hartmann U, Queudeville M, Feucht J, Ost M, Koch MS, Malaval C, Mezger M, Schober S, Weber S, Michaelis S, Lange V, Lang P, Handgretinger R, Döring M
Drug Design, Development and Therapy 2019, 13:3439-3451
Published Date: 30 September 2019
![Noteworthy comment: The review article is a comprehensive overview of clinical applications in the blinatumomab immunotherapy in R/R precursor B-cell ALL patients. The paper provides deep multi-aspect analysis of current clinical trials on blinatumomab and indicates essential checkpoints for this therapy applicability.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
Queudeville M, Handgretinger R, Ebinger M
OncoTargets and Therapy 2017, 10:3567-3578
Published Date: 19 July 2017